ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therap... ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. 더 보기
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.995 | -7.55538723727 | 26.405 | 27.105 | 23.63 | 148816 | 24.898038 | CS |
4 | -1.225 | -4.7786229764 | 25.635 | 28.505 | 23.63 | 158303 | 26.15222684 | CS |
12 | -6.93 | -22.1123165284 | 31.34 | 36.37 | 23.63 | 149065 | 28.35454184 | CS |
26 | 4.52 | 22.7249874309 | 19.89 | 36.37 | 18.39 | 201864 | 26.34202924 | CS |
52 | 0.41 | 1.70833333333 | 24 | 36.37 | 14.35 | 174102 | 23.44564854 | CS |
156 | 0.41 | 1.70833333333 | 24 | 36.37 | 14.35 | 174102 | 23.44564854 | CS |
260 | 0.41 | 1.70833333333 | 24 | 36.37 | 14.35 | 174102 | 23.44564854 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관